Stock RVNC REVANCE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
2.7 USD -6.90% Intraday chart for Revance Therapeutics, Inc. -4.93% -69.28%
May. 10 Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating MT
May. 10 Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revance to Participate in Upcoming Investor Conferences
BU
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY for the Treatment of Cervical Dystonia
AQ
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
BU
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
BU
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
BU
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives
AQ
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
BU
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation
AQ
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
BU
Revance Announces Proposed Public Offering of Common Stock
BU
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
BU
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
BU
Revance to Participate in Upcoming Investor Conferences
BU
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
BU
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
BU
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
BU
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVNC Stock
  4. News Revance Therapeutics, Inc.
  5. Press Releases